{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:48:37Z","timestamp":1783122517007,"version":"3.54.6"},"reference-count":30,"publisher":"American Society for Microbiology","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"GSK","award":["RDP-CW591261"],"award-info":[{"award-number":["RDP-CW591261"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Novel antimicrobials are needed to treat rising nontuberculous mycobacteria (NTM) infections. Using standard broth microdilution methods, 68 NTM isolates were tested against gepotidacin, a new, first-in-class, oral triazaacenaphthylene bacterial topoisomerase inhibitor. MICs varied (0.25 to &gt;64 \u00b5g\/mL) with the lowest being\n              <jats:italic>M. fortuitum<\/jats:italic>\n              complex (0.25\u20138 \u00b5g\/mL),\n              <jats:italic>M. mucogenicum<\/jats:italic>\n              complex (1\u20132 \u00b5g\/mL),\n              <jats:italic>M. kansasii<\/jats:italic>\n              (0.25\u20138 \u00b5g\/mL), and\n              <jats:italic>M. marinum<\/jats:italic>\n              (4\u201316 \u00b5g\/mL). Testing greater numbers of some species is suggested to better understand gepotidacin activity against NTM.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.01684-23","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T13:00:24Z","timestamp":1713963624000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["<i>In vitro<\/i>\n            activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM)"],"prefix":"10.1128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-1169","authenticated-orcid":false,"given":"Barbara A.","family":"Brown-Elliott","sequence":"first","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Mycobacteria\/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgie","family":"Bush","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Mycobacteria\/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dolores","family":"Hughes","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Mycobacteria\/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Mycobacteria\/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase A.","family":"Weikel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon B.","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard J.","family":"Wallace","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at Tyler, Mycobacteria\/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05030-11"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-014-0032-2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0027-2016"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02950-14"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2021.11.007"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207983"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210927"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01612-13"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa520"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.1.65"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00199-20"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02196-7"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01525-22"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky162"},{"key":"e_1_3_2_22_2","unstructured":"GSK ANNOUNCES positive headline results from EAGLE-1 phase III trial for Gepotidacin in uncomplicated Urogenital Gonorrhoea (GC). 2024. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-positive-headline-results-from-eagle-1-phase-iii-trial-for-gepotidacin-in-uncomplicated-urogenital-gonorrhoea-gc\/"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01492-21"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy145"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5699-5708.2003"},{"key":"e_1_3_2_26_2","volume-title":"Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing. 2nd ed. CLSI Guideline MM18","edition":"2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh523"},{"key":"e_1_3_2_28_2","volume-title":"Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","year":"2023","unstructured":"Clinical and Laboratory Standards Institute. 2023. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 2nd ed. CLSI Supplement M24S. Wayne, PA.","edition":"2"},{"key":"e_1_3_2_29_2","volume-title":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","year":"2018","unstructured":"Clinical and laboratory standards Institute. 2018. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 3rd ed. CLSI M24. Wayne, PA.","edition":"3"},{"key":"e_1_3_2_30_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and laboratory standards Institute","year":"2024","unstructured":"Clinical and laboratory standards Institute. 2024. Performance standards for antimicrobial susceptibility testing. 34th ed. CLSI Supplement M100. Clinical and Laboratory Standards Institute.","edition":"34"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00564-22"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01684-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01684-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T13:00:31Z","timestamp":1713963631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01684-23"}},"subtitle":[],"editor":[{"given":"Jared A.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":30,"alternative-id":["10.1128\/aac.01684-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.01684-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"2023-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01684-23"}}